21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of...
00:12 , Sep 12, 2017 |  BC Extra  |  Company News

Achillion down after J&J drops HCV compound

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $1.08 (22%) to $3.83 Monday after Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue...
01:42 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

JNJ-4178: Ph IIb OMEGA-1 started

Achillion said Johnson & Johnson began the open-label, international Phase IIb OMEGA-1 trial to evaluate oral JNJ-4178 once daily for 6 or 8 weeks in about 300 patients without cirrhosis. JNJ-4178 comprises 800 mg AL-335...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Odalasvir: Interim Phase IIa data

Achillion reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335, odalasvir and Olysio simeprevir....
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

AL-335: Interim Phase IIa data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN, New Haven, Conn.) reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335,...
07:00 , Sep 23, 2016 |  BC Extra  |  Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion...
08:00 , Feb 29, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg2/26 clsAchillion Pharmaceuticals Inc. (NASDAQ:ACHN)BairdBrian SkorneyUpgradeOutperform (from neutral)10%$7.35 Skorney upgraded and maintained his $10 target ahead of HCV data from a Phase IIa trial of Achillion's odalasvir plus...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

AL-335: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio/ Sovriad simeprevir, AL-335 and odalasvir ( ACH-3102) for 4, 6 or 8 weeks in about 60 patients....
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

Odalasvir: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio/ Sovriad simeprevir, AL-335 and odalasvir for 4, 6 or 8 weeks in about 60 patients. J&J’s...